Online inquiry

IVTScrip™ mRNA-Anti-MAPT, LY-3303560(Cap 1, 2-Thio-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ10632MR)

This product GTTS-WQ10632MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets MAPT gene. The antibody can be applied in Dementia research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001123066.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 4137
UniProt ID P10636
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-MAPT, LY-3303560(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) (GTTS-WQ10632MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ8025MR IVTScrip™ mRNA-Anti-CD52, GZ-402668(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA GZ-402668
GTTS-WQ14452MR IVTScrip™ mRNA-Anti-IGF1R, RO4858696-000(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA RO4858696-000
GTTS-WQ15545MR IVTScrip™ mRNA-Anti-NGcGM3, UNII-52G405U1E5(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA UNII-52G405U1E5
GTTS-WQ15297MR IVTScrip™ mRNA-Anti-EGFR, Theraloc(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA Theraloc
GTTS-WQ6102MR IVTScrip™ mRNA-Anti-IL23A, CNTO-1959(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA CNTO-1959
GTTS-WQ872MR IVTScrip™ mRNA-Anti-PRLR, ABBV-176(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA ABBV-176
GTTS-WQ6878MR IVTScrip™ mRNA-Anti-CX3CL1, E-6011(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA E-6011
GTTS-WQ8014MR IVTScrip™ mRNA-Anti-CD52, GZ-402668(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA GZ-402668
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW